{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:27:18Z","timestamp":1787016438527,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1124\/jpet.121.000988","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T11:38:38Z","timestamp":1653305918000},"page":"54-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Preclinical Assessment of the Abuse Potential of Purified Botanical Cannabidiol: Self-Administration, Drug Discrimination, and Physical Dependence"],"prefix":"10.1016","volume":"382","author":[{"given":"R.A.","family":"Gray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Heal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.R.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.R.","family":"Gerak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Javors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.P.","family":"France","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.121.000988_bib1","article-title":"The dose-dependent analgesic effects, abuse liability, safety and tolerability of oral cannabidiol in healthy humans","author":"Arout","year":"2021","journal-title":"Br J Clin Pharmacol."},{"key":"10.1124\/jpet.121.000988_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","article-title":"Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers","volume":"172","author":"Babalonis","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.121.000988_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00213-020-05712-8","article-title":"Cannabidiol: pharmacology and therapeutic targets","volume":"238","author":"Britch","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.121.000988_bib4","unstructured":"Center for Drug Evaluation and Research (CDER)\/Food and Drug Administration (FDA) (2017) Guidance for Industry Assessment of Abuse Potential of Drugs. https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm198650.pdf."},{"key":"10.1124\/jpet.121.000988_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1124\/jpet.121.000988_bib6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"key":"10.1124\/jpet.121.000988_bib7","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.121.000988_bib8","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"10.1124\/jpet.121.000988_bib9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/epi.14628","article-title":"Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial","volume":"60","author":"Devinsky","year":"2019","journal-title":"Epilepsia"},{"key":"10.1124\/jpet.121.000988_bib10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF00426467","article-title":"Inter-animal olfactory cues in operant drug discrimination procedures in rats","volume":"73","author":"Extance","year":"1981","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.121.000988_bib11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","article-title":"Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial","volume":"7","author":"Freeman","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1124\/jpet.121.000988_bib12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/BF02244254","article-title":"Evaluation of the dependence potential of the selective 5-H1A agonist ipsapirone in rats and of its effects on benzodiazepine withdrawal","volume":"103","author":"Goudie","year":"1991","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.121.000988_bib13","doi-asserted-by":"crossref","first-page":"974","DOI":"10.2174\/1570159X17666190603171901","article-title":"Cannabidiol Adverse Effects and Toxicity","volume":"17","author":"Huestis","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"10.1124\/jpet.121.000988_bib14","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals with Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial","volume":"176","author":"Hurd","year":"2019","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.121.000988_bib15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","article-title":"Molecular targets of cannabidiol in neurological disorders","volume":"12","author":"Ibeas Bih","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1124\/jpet.121.000988_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/jpet.119.261511","article-title":"OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention","volume":"372","author":"Maguire","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.121.000988_bib17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.121.000988_bib18","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","article-title":"Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings","volume":"38","author":"Morgan","year":"2013","journal-title":"Addict Behav"},{"key":"10.1124\/jpet.121.000988_bib19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1037\/pha0000272","article-title":"Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research","volume":"27","author":"Nona","year":"2019","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1124\/jpet.121.000988_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.121.000988_bib21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.yebeh.2018.07.027","article-title":"Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial","volume":"88","author":"Schoedel","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1124\/jpet.121.000988_bib22","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"10.1124\/jpet.121.000988_bib23","first-page":"48950","article-title":"Schedules of Controlled Substances: Placement in Schedule V of Certain FDA-Approved Drugs Containing Cannabidiol; Corresponding Change to Permit Requirements","volume":"83","year":"2018","journal-title":"Fed Regist"},{"key":"10.1124\/jpet.121.000988_bib24","unstructured":"US Food and Drug Administration (FDA) (2018) FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. FDA News Release, June 25, 2018 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms Accessed July 18, 2021."}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652400288X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652400288X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.121.000988","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T18:02:50Z","timestamp":1743184970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652400288X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S002235652400288X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.121.000988","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical Assessment of the Abuse Potential of Purified Botanical Cannabidiol: Self-Administration, Drug Discrimination, and Physical Dependence","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.121.000988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}